| 16.64 0.24 (1.46%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.65 | 1-year : | 20.13 |
| Resists | First : | 16.82 | Second : | 17.23 |
| Pivot price | 16.69  |
|||
| Supports | First : | 16.15 | Second : | 13.44 |
| MAs | MA(5) : | 16.39 |
MA(20) : | 16.78 |
| MA(100) : | 16.45 |
MA(250) : | 11.22 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 24.5 |
D(3) : | 17.3 |
| RSI | RSI(14): 48.5 |
|||
| 52-week | High : | 17.57 | Low : | 3.67 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RLYB ] has closed above bottom band by 45.4%. Bollinger Bands are 0.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.81 - 16.87 | 16.87 - 16.92 |
| Low: | 16.28 - 16.36 | 16.36 - 16.42 |
| Close: | 16.52 - 16.64 | 16.64 - 16.74 |
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
Fri, 23 Oct 2026
Rallybio Corporation Estimates – NASDAQ:RLYB - TradingView
Thu, 22 Oct 2026
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB - Business Wire
Wed, 21 Oct 2026
Form 4 Rallybio Corp: Paula Soteropoulos (Director) For: 16 October By Investing.com - Investing.com South Africa
Tue, 20 Oct 2026
Form 4 Rallybio Corp: Helen M. Boudreau (Director) For: 16 October - Investing.com India
Mon, 19 Oct 2026
RLYB Forecast — Price Target — Prediction for 2027 - TradingView
Wed, 14 Oct 2026
A $215M financing would split ownership three ways in Rallybio (Nasdaq: RLYB)'s proposed Avenzo merger. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -14 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 5.31e+006 (%) |
| Held by Institutions | 1.74e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.18e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8 |
| Profit Margin | 7 % |
| Operating Margin | 51.2 % |
| Return on Assets (ttm) | -3 % |
| Return on Equity (ttm) | 935.4 % |
| Qtrly Rev. Growth | 64.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.538e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 2.07 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 49240 |
| Forward Dividend | 54940 |
| Dividend Yield | 295913% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|